Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel
Open Access
- 14 October 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 5070-5084
Abstract
Hematotoxicity is the most frequent severe toxicity after chimeric antigen receptor T-cell (CAR-T) therapy. However, limited data exist on risk factors and outcomes for hematotoxicity for children and young adults (CAYAs) with B-acute lymphoblastic leukemia treated with tisagenlecleucel. We conducted a multi-institutional study involving 326 CAYAs, with 144 evaluable in an initial training cohort and 141 evaluable in a validation cohort, through the Pediatric Real-World CAR Consortium to characterize the incidence and outcomes of prolonged severe neutropenia (PSN) and to develop a predictive risk score for PSN, tailored for use in this population. The incidence of PSN, defined as an absolute neutrophil count of <0.5 x 103 cells per μL for ≥30 days, was 15.3% in the initial training cohort and 21% in the validation cohort. Development of PSN was associated with inferior overall survival (P < .001), relapse-free survival (P = .01), higher nonrelapse mortality (P = .003), and a greater risk of infections within 30 days (P = .03). Multivariable penalized regression analysis identified key risk factors for PSN, which included preinfusion C-reactive protein and bone marrow disease burden, and postinfusion peak ferritin and occurrence of severe cytokine release syndrome, which were used to create the CytoRisk score. In the validation cohort, the CytoRisk score discriminated between patients with and without PSN (area under the curve, 0.90; specificity, 93%; sensitivity, 71%; positive predictive value, 74%; and negative predictive value, 92%). The CytoRisk score may be used to a priori identify patients at highest risk of PSN and overall worse outcomes.Keywords
This publication has 55 references indexed in Scilit:
- Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumorsCytotherapy, 2024
- The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLAmerican Journal of Hematology, 2023
- Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myelomaCytotherapy, 2023
- Allogeneic CD34+ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infectionPediatric Blood & Cancer, 2022
- The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T‐cell therapyAmerican Journal of Hematology, 2021
- Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid MalignanciesTransplantation and Cellular Therapy, 2021
- Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T CellsTransplantation and Cellular Therapy, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009